SHAREHOLDER ALERT: Monteverde & Associates PC Invites ImmunoCellular Therapeutics, Ltd. Shareholders with Losses To Contact The Firm Immediately - IMUC

NEW YORK, June 1, 2017

The lawsuit is based on whether ImmunoCellular Therapeutics and its executives violated federal securities law by issuing false and/or misleading statements that ImmunoCellular retained Lidingo Holdings, LLC to publish articles designed to unlawfully promote the Company. Investors were led to believe that the Company's clinical studies for its lead product candidate, ICT-107 were going well in order to inflate ImmunoCellular's share price.

After market close on December 11, 2013, the Company revealed that the primary endpoint for its ICT-107 Phase II study "did not reach statistical significance" because it failed to increase overall survival in patients diagnosed with glioblastoma multiforme. When the information was revealed to the public, the value of ImmunoCellular stock dropped, causing losses to its shareholders.

Mr. Monteverde would like to personally discuss with you how to potentially recover your monetary losses, if incurred during the Class Period.

If you wish to serve as lead plaintiff, you must move the Court no later than June 30, 2017.  Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

Click here for more information: http://monteverdelaw.com/securities/.  It is free and there is no cost or obligation to you.